Cross-Border Transactions INTERNATIONAL PRACTICES

WilmerHale's corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.


Our team counsels companies across industries, drawing on the firm's internationally recognized life sciences, technology and financial services capabilities, to counsel pharmaceutical companies, medical device developers, software and Internet companies, semiconductor manufacturers, fin tech providers and a wide range of other clients. Our transactional lawyers are backed by regulatory lawyers with deep experience in Committee on Foreign Investment in the United States (CFIUS) and Foreign Corrupt Practices Act (FCPA) requirements, as well as by securities, tax, real estate, antitrust and intellectual property practitioners who are ready to meet the diverse needs of all clients.

Venture Capital

Examples of our experience include:

  • representing biopharmaceutical company Celtaxsys in a $40 million Series D financing. In connection with the financing, Celtaxsys entered into an award and development agreement with Cystic Fibrosis Foundation Therapeutics and licensed its rights in several Eastern European and Asian countries;
  • representing UK company MirriAd in its $15 million Series A round. MirriAd, which makes technology that enables brands to advertise by integrating into popular TV content and music videos, has an office in India and is expanding in the US;
  • representing Viamet Pharmaceuticals Holdings in investments from US, Irish and other UK-based investors; and
  • representing UXPin, a user experience design tool company with teams in Silicon Valley and Poland, in seed and early-stage financings.

Mergers & Acquisitions

Examples of our experience include:

  • representing UK game-maker NaturalMotion in its $527 million acquisition of Zynga, the world's leading provider of social game services;
  • representing AVIC International Holding (Zhuhai) Company in its $230 million acquisition of California-based Align Aerospace Holding, as well as in its CFIUS and antitrust filings and in obtaining Chinese regulatory approval for the acquisition;
  • representing Bermuda-based Bacardi Limited in its acquisition of Angel's Share Brands, marking Bacardi's entry into the bourbon category; and
  • representing Lufthansa in numerous M&A transactions, including its acquisition of a 30% stake in bmi British Midland, and joint ventures for its cargo and aircraft maintenance businesses.

IPO/Capital Markets

Examples of our experience include:

  • representing Yandex N.V., the operator of the leading Search engine in Russia, in its initial public offering;
  • representing UK-based biopharmaceutical company Summit Therapeutics in its initial public offering;
  • representing Austrian-based client Nabriva Therapeutics in its initial public offering;
  • representing the underwriters in UK-based biopharmaceutical company Adaptimmune Therapeutics plc's initial public offering; and
  • representing Danaher Corporation in a €2.7 billion offering of senior notes.

Strategic Alliances, Outsourcing & Licensing

Examples of our experience include:

  • counseling on the formation of the Star Alliance—the largest airline alliance in the world, comprising more than 15 international carriers;
  • representing TiVo in a Build-Operate-Transfer M&A and outsourcing deal with Ness USA, in which TiVo contracted  Ness to create a dedicated technology facility in Iasi, Romania, from which Ness will provide application development services to TiVo;
  • representing the National Hockey League in its licensing of the NHL Centre Ice television package in Canada;
  • representing Ophthotech in an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals related to the treatment of wet age-related macular degeneration; and
  • counseling Merrimack Pharmaceuticals in an exclusive license and collaboration agreement with Baxter International for the development and commercialization a development-stage drug for pancreatic cancer outside of the United States and Taiwan.